Member Login


treatments for alpha-1 antitrypsin deficiency

Augmentation therapy (weekly infusions of antitrypsin to protect the lungs) is not subsidised by the Australian Government as it was deemed by the Medical Services Advisory Committee (MSAC) to be too expensive and not clinically effective (see MSAC report on Resources page under Links). Private purchase is possible under the Special Access Scheme pathway and costs on average $100,000 per annum (dependent on body weight) and requires access to an infusion service which may have additional costs depending on health insurance.  Some patients have been able to access augmentation therapy due to clinical trial participation e.g. the Grifols Sparta Trial.